TetraLogic Pharmaceuticals Corp
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to… Read more
TetraLogic Pharmaceuticals Corp (TLOG) - Total Assets
Latest total assets as of September 2016: $42.79 Million USD
Based on the latest financial reports, TetraLogic Pharmaceuticals Corp (TLOG) holds total assets worth $42.79 Million USD as of September 2016.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TetraLogic Pharmaceuticals Corp - Total Assets Trend (2011–2015)
This chart illustrates how TetraLogic Pharmaceuticals Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TetraLogic Pharmaceuticals Corp - Asset Composition Analysis
Current Asset Composition (December 2015)
TetraLogic Pharmaceuticals Corp's total assets of $42.79 Million consist of 34.3% current assets and 65.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $417.81K | 0.7% |
| Intangible Assets | $41.58 Million | 64.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2015)
This chart illustrates how TetraLogic Pharmaceuticals Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TetraLogic Pharmaceuticals Corp's current assets represent 34.3% of total assets in 2015, a decrease from 97.9% in 2011.
- Cash Position: Cash and equivalents constituted 23.9% of total assets in 2015, down from 61.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 64.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 64.9% of total assets.
TetraLogic Pharmaceuticals Corp Competitors by Total Assets
Key competitors of TetraLogic Pharmaceuticals Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TetraLogic Pharmaceuticals Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TetraLogic Pharmaceuticals Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TetraLogic Pharmaceuticals Corp is currently not profitable relative to its asset base.
TetraLogic Pharmaceuticals Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.48 | 5.95 | 1.49 |
| Quick Ratio | 0.48 | 5.95 | 1.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.96 Million | $ 26.08 Million | $ 1.54 Million |
TetraLogic Pharmaceuticals Corp - Advanced Valuation Insights
This section examines the relationship between TetraLogic Pharmaceuticals Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -45.9% |
| Total Assets | $64.02 Million |
| Market Capitalization | $2.18K USD |
Valuation Analysis
Below Book Valuation: The market values TetraLogic Pharmaceuticals Corp's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TetraLogic Pharmaceuticals Corp's assets decreased by 45.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TetraLogic Pharmaceuticals Corp (2011–2015)
The table below shows the annual total assets of TetraLogic Pharmaceuticals Corp from 2011 to 2015.
| Year | Total Assets | Change |
|---|---|---|
| 2015-12-31 | $64.02 Million | -45.88% |
| 2014-12-31 | $118.29 Million | +113.13% |
| 2013-12-31 | $55.50 Million | +1035.75% |
| 2012-12-31 | $4.89 Million | -70.11% |
| 2011-12-31 | $16.35 Million | -- |